Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taxane-based chemotherapy · 1 trial · 1 indication
Adverse events (including laboratory abnormalities) were assessed by the investigator according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) grading systems.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| bevacizumab [Avastin] | DRUG | 10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle |
| Taxane-based chemotherapy | DRUG | As prescribed |
Inclusion Criteria: * patients, \>=18 years of age; * HER-2 negative adenocarcinoma of the breast, with locally recurrent or metastatic disease; (HER-2 positive patients only if previously treated with Herceptin in the adjuvant setting; * candidates for chemotherapy. Exclusion Criteria: * previou...
Top 20 of 92 competitors
Taxane-based chemotherapy is used for the treatment of locally recurrent or metastatic breast cancer. It was studied in a Phase 3 clinical trial in combination with Avastin (bevacizumab) for this patient population.
Taxane-based chemotherapy is developed by Roche Holding AG, which trades under the ticker RHHBY. The company conducted a Phase 3 study of this therapy in combination with bevacizumab for breast cancer.
Taxane-based chemotherapy is in Phase 3 clinical development. A Phase 3 trial, NCT00448591, has been completed, and the drug remains investigational for the treatment of breast cancer.
Taxane-based chemotherapy has been studied in one completed Phase 3 clinical trial, NCT00448591, titled 'A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.' The trial enrolled 2,296 participants.
Taxane-based chemotherapy is investigational and still in clinical development. It has not been reported as FDA approved, and its Phase 3 trial for breast cancer has been completed but no approval status has been indicated.